GCG and obesity disorder: We found further evidence that a combinatory treatment with PYY3-36 and a GLP-1 agonist (liraglutide) can exert an additive effect on body weight loss similar to that of RYGB, which further underlines their possible usability and efficacy for obesity treatment.